AYTU BioPharma
AYTU
39 hedge funds and large institutions have $12.2M invested in AYTU BioPharma in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 14 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
0.26% less ownership
Funds ownership: 1.03% → 0.77% (-0.26%)
22% less funds holding
Funds holding: 50 → 39 (-11)
26% less call options, than puts
Call options by funds: $194K | Put options by funds: $261K
53% less capital invested
Capital invested by funds: $26M → $12.2M (-$13.7M)
79% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.26M |
| 2 |
Renaissance Technologies
New York
|
+$688K |
| 3 |
D.E. Shaw & Co
New York
|
+$366K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$237K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$200K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$6.72M |
| 2 |
VF
Virtu Financial
New York
|
-$510K |
| 3 |
E
Ergoteles
New York
|
-$378K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$301K |
| 5 |
Millennium Management
New York
|
-$301K |
AYTU Hedge Fund Activity: Q3 2021 in Review
39 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2021, worth a combined $12.2M — down 53% from $26M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of AYTU and 3 opened new positions — a net loss of 11 holders — while 10 trimmed existing stakes and 17 added.
The largest buyer was Morgan Stanley, adding an estimated $1.26M. The largest seller was Armistice Capital, exiting entirely with an estimated $6.72M sold.
- 39 institutional investors held AYTU BioPharma (AYTU) as of Q3 2021, down from 50 in Q2 2021.
- Funds reported $12.2M of AYTU BioPharma stock for Q3 2021, down 53% quarter-over-quarter.
- 3 funds opened new AYTU BioPharma positions in Q3 2021 and 14 closed out, a net change of -11 holders.
- The largest AYTU BioPharma buyer in Q3 2021 was Morgan Stanley, an estimated $1.26M added.
- The largest AYTU BioPharma seller in Q3 2021 was Armistice Capital, an estimated $6.72M sold.
Based on aggregated 13F filings for Q3 2021.